Annual Meeting of the National Reference Centers
Friday May 22th, 2026
Opening
Clinical cases
Corentin BOULARD
Victor FAGES
Marie MATIGNON
Eulalie LEROUX
Ornela RIZZO
Stéphanie CORDEIL
Arnaud JACCARD
Updates on ongoing clinical research: Isamyp, Venamy, Teclistamy, ABBV-383, Linker AL, CAEL-101 for stage IIIA and IIIB patients – Murielle ROUSSEL, Limoges
Predicting the pathogenic potential of monoclonal light chain using artificial intelligence – Virginie PASCAL, Limoges
2026 Activities and Projects of the French Amyloidosis Patient Association – Pascal COMBES, Barbara MAZZOLINI
Role of defibrillators and new developments in the cardiological management of AL amyloidosis – Silvia OGHINA, Créteil
Comparison of cardiac involvement in LCDD and amyloidosis, Martin NICOL, Paris
Organization of AL amyloidosis management in Germany: prognostic factors in AL amyloidosis and therapeutic strategies in 2026 – Stephan SCHÖNLAND, Heidelberg
Management of very severe amyloidosis: (albumin <10 g/L, Mayo stage IIIc, hepatic involvement with high bilirubin levels, severe neuropathies) – Nathalie MEULEMAN, Marie-Christine VEKEMANS, Brussels
Update on kidney transplantation in MGRS: experience from the Poitiers nephrology team – Adrien AGNOLA
Review of MGCS cutaneous MDT meetings – Bertrand ARNULF, Thibaud MAHÉVAS, Paris
10 years of Amyloidosis and MGRS MDT meetings – David LAVERGNE, Arnaud JACCARD, Limoges